No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Beijing Biostar Pharmaceuticals Cancer Drug Receives US FDA Approval
Huahaotian Medicine-B (02563.HK): The USA Food and Drug Administration has approved the use of Urotolone capsules as the first-line treatment in an international multicenter clinical study for advanced gastric cancer stage II/III.
On February 5, Gelonghui announced that Huahao Zhongtian Pharmaceutical-B (02563.HK) has received approval from the USA Food and Drug Administration (FDA) for an important overseas pipeline of the group, UTD2 capsules, in combination with capecitabine and oxaliplatin for first-line treatment of PD-L1 negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma ("this combination therapy") in an international multicenter Phase II/III registration clinical study ("BG02-2404"). The UTD2, developed using the group's unique synthetic biology technology platform, has successfully completed Phase I clinical trials in the USA, and its safety.
After maintaining a two-month upward trend, Huahao Zhongtian Pharmaceutical-B (02563) saw a single-day maximum decline of over 40%.
If the stock price trend does not "engulf" the large bearish candlestick formed on December 30 and does not produce a significant bullish candlestick with increasing volume recently, it indicates that the downside of the stocks may not yet have reached the end in the short term, and bottom signals have not yet appeared.
Hong Kong stock fluctuation | Huahua Zhongtian Pharmaceutical-B (02563) plummeted over 37%, erasing all gains since its listing, with the Market Cap shrinking to 7.2 billion HKD.
Huahao Zhongtian Medicine-B (02563) plummeted over 37%. The stock was listed on October 31 of this year and rose 30% on the first day, after which the stock price steadily increased. As of the time of writing, it has fallen 37.18%, trading at 19.82 Hong Kong dollars, with a transaction amount of 11.9471 million Hong Kong dollars.
[IPO Monthly Report] The hot market for Hong Kong IPOs in October remains unabated. The oversubscription ratio of Karotex was 1346 times, and China Resources Beverage may become the "capital freezing king" of the year.
In September, Midea Group Co., Ltd. (00300) raised 35.7 billion yuan, becoming the largest in the Hong Kong stock market since February 2021, the largest in Asia in the first three quarters of 2024, and the second largest in the world by 2024. The Chief Executive Officer of HKEX, Bonnie Chan Yi-Ting, stated: "Recently, the HKEX welcomed the largest in Asia and the second largest in the world in terms of new stock listings this year. Refinancing activities are also very active, demonstrating the depth and attractiveness of our market. The number of new stock listing applications further consolidates Hong Kong's position as the preferred new stock fundraising center in Asia. In addition, Alibaba has converted to a dual primary listing and was subsequently included in the Stock Connect."
